Back to search results

A Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Afimkibart (RO7790121) in Children With Moderately to Severely Active Ulcerative Colitis

Abroad (travel likely)RecruitingPHASE3

Conditions

Moderately to Severely Active Ulcerative Colitis

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • University of South Florida, Tampa, Florida, United States

  • Children's Healthcare of Atlanta, Atlanta, Georgia, United States

  • NYU Langone Health, New York, New York, United States

  • Mater Hospital Brisbane, South Brisbane, Queensland, Australia

  • Royal Children's Hospital, Parkville, Victoria, Australia

  • Perth Children's Hospital, Nedlands, Western Australia, Australia

  • Children's Hospital ZheJiang University School of Medicine, Hangzhou, Zhejiang, China

  • Emmed Research, Pretoria, South Africa

  • National Taiwan University Hospital, Taipei, Taiwan

  • Chulalongkorn University, Bangkok, Thailand

  • Siriraj Hospital, Bangkok, Thailand

  • Ramathibodi Hospital, Bangkok, Thailand

  • Birmingham Children's Hospital, Birmingham, United Kingdom

  • Addenbrooke's Hospital, Cambridge, United Kingdom

  • Sheffield Childrens Hospital, Sheffield, United Kingdom

Study leads

  • Clinical Trials

    Study Director

    Hoffmann-La Roche

View source on ClinicalTrials.gov(opens in a new tab)